title: [Brucellosis at the dawn of the 21st century].
abstract: Human brucellosis is now a rare disease in countries where eradication programs (especially vaccination) against brucellosis in cattle, sheep, and goats have been successfully implemented. In France, fewer than 50 brucellosis cases are annually notified to the National Institute for Infection Surveillance. Human brucellosis, however, remains endemic in the Mediterranean basin, Middle East, Western Asia, Africa, and South America. Shortcomings of standard diagnostic methods for brucellosis (variable sensitivity of culture, frequent serological cross reactions) have been only partially resolved by modern molecular biology techniques. There are now 3 new challenges to be faced by the medical and veterinarian community: the expanding wildlife reservoir of brucellosis, with a possible impact on domestic animals; the emergence of Brucella. melitensis infections in cattle, for which prophylactic efficacy of available vaccines has not been established; and recent recognition of a huge animal reservoir of Brucella species in marine mammals, for which the potential virulence in humans remains unknown.
authors.affiliation: Service de bactériologie-virologie, université Joseph-Fourier, CHU de Grenoble, BP 217, 38043 Grenoble cedex, France. mmaurine@chu-grenoble.fr
authors.forename: M
authors.initials: M
authors.lastname: Maurin
mesh_terms: D000818:Animals; D000835:Animals, Wild; D002002:Brucella / Q000472:pathogenicity*; D002006:Brucellosis / Q000453:epidemiology* / Q000473:pathology / Q000635:transmission; D002007:Brucellosis, Bovine / Q000517:prevention & control / Q000635:transmission; D002417:Cattle; D005602:France / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D019083:Mediterranean Region / Q000453:epidemiology; D014612:Vaccines / Q000627:therapeutic use; D014774:Virulence; D015047:Zoonoses
chemical_list: D014612:Vaccines